News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
868,705 Results
Type
Article (87856)
Company Profile (824)
Press Release (780010)
Multimedia
Podcasts (190)
Webinars (28)
Section
Business (233205)
Career Advice (4144)
Deals (39859)
Drug Delivery (145)
Drug Development (91392)
Employer Resources (203)
FDA (18373)
Job Trends (17416)
News (397806)
Policy (39956)
Tag
Academia (3006)
Academic (2)
Accelerated approval (31)
Adcomms (36)
Allergies (142)
Alliances (56981)
ALS (179)
Alzheimer's disease (1776)
Antibody-drug conjugate (ADC) (327)
Approvals (18530)
Artificial intelligence (603)
Autoimmune disease (148)
Automation (34)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (198)
Biotechnology (488)
Bladder cancer (156)
Brain cancer (63)
Breast cancer (639)
Cancer (4866)
Cardiovascular disease (427)
Career advice (3566)
Career pathing (40)
CAR-T (300)
CDC (59)
Celiac Disease (1)
Cell therapy (807)
Cervical cancer (37)
Clinical research (76830)
Collaboration (1705)
Company closure (5)
Compensation (1115)
Complete response letters (69)
COVID-19 (2984)
CRISPR (95)
C-suite (810)
Cystic fibrosis (153)
Data (6090)
Decentralized trials (2)
Denatured (70)
Depression (139)
Diabetes (518)
Diagnostics (7200)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (292)
Drug pricing (214)
Drug shortages (36)
Duchenne muscular dystrophy (231)
Earnings (99970)
Editorial (60)
Employer branding (25)
Employer resources (173)
Events (134889)
Executive appointments (1019)
FDA (21398)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (24)
Funding (1509)
Gene editing (206)
Generative AI (62)
Gene therapy (650)
GLP-1 (1103)
Government (5431)
Grass and pollen (8)
Guidances (382)
Healthcare (20941)
HIV (58)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (286)
Immuno-oncology (48)
Indications (80)
Infectious disease (3264)
Inflammatory bowel disease (200)
Inflation Reduction Act (17)
Influenza (116)
Intellectual property (233)
Interviews (816)
IPO (17951)
IRA (60)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (89)
Layoffs (656)
Leadership (39)
Legal (10156)
Liver cancer (97)
Longevity (14)
Lung cancer (663)
Lymphoma (368)
Machine learning (42)
Management (66)
Manufacturing (797)
MASH (171)
Medical device (14996)
Medtech (15040)
Mergers & acquisitions (22933)
Metabolic disorders (1349)
Multiple sclerosis (157)
NASH (23)
Neurodegenerative disease (336)
Neuropsychiatric disorders (92)
Neuroscience (3047)
NextGen: Class of 2026 (7706)
Non-profit (5107)
Now hiring (62)
Obesity (649)
Opinion (330)
Ovarian cancer (160)
Pain (197)
Pancreatic cancer (221)
Parkinson's disease (288)
Partnered (38)
Patents (486)
Patient recruitment (447)
Peanut (60)
People (66779)
Pharmaceutical (145)
Pharmacy benefit managers (31)
Phase I (23741)
Phase II (33335)
Phase III (25134)
Pipeline (4473)
Policy (327)
Postmarket research (3554)
Preclinical (10679)
Press Release (72)
Prostate cancer (237)
Psychedelics (53)
Radiopharmaceuticals (295)
Rare diseases (848)
Real estate (7437)
Recruiting (80)
Regulatory (28794)
Reports (65)
Research institute (2719)
Resumes & cover letters (651)
Rett syndrome (26)
RNA editing (17)
RSV (82)
Schizophrenia (157)
Series A (252)
Series B (187)
Service/supplier (30)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (174)
Sponsored (47)
Startups (4332)
State (2)
Stomach cancer (20)
Supply chain (110)
Tariffs (97)
The Weekly (118)
Vaccines (1123)
Venture capital (91)
Weight loss (447)
Women's health (82)
Worklife (21)
Date
Today (61)
Last 7 days (935)
Last 30 days (1931)
Last 365 days (33235)
2026 (1016)
2025 (33228)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1289)
Alabama (87)
Alaska (7)
Arizona (336)
Arkansas (14)
Asia (51455)
Australia (9031)
California (11197)
Canada (3238)
China (1114)
Colorado (469)
Connecticut (488)
Delaware (338)
Europe (118231)
Florida (1639)
Georgia (356)
Hawaii (3)
Idaho (68)
Illinois (930)
India (64)
Indiana (531)
Iowa (23)
Japan (408)
Kansas (132)
Kentucky (42)
Louisiana (29)
Maine (82)
Maryland (1429)
Massachusetts (8300)
Michigan (348)
Minnesota (643)
Mississippi (6)
Missouri (136)
Montana (35)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3043)
New Mexico (33)
New York (2974)
North Carolina (1572)
North Dakota (10)
Northern California (5324)
Ohio (342)
Oklahoma (22)
Oregon (54)
Pennsylvania (2250)
Puerto Rico (20)
Rhode Island (49)
South America (1656)
South Carolina (62)
South Dakota (1)
Southern California (4308)
Tennessee (172)
Texas (1771)
United States (40598)
Utah (335)
Vermont (1)
Virginia (280)
Washington D.C. (85)
Washington State (943)
West Virginia (4)
Wisconsin (122)
Wyoming (2)
There are 868,705 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens
Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 million IPO target.
January 12, 2026
·
2 min read
·
Tristan Manalac
Policy
Flagship CEO Calls Out Attacks on Science, Warns of China Dominance
In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a reversion to the pain and suffering of past diseases due to “growing contempt” in the U.S. for the scientific method.
January 12, 2026
·
4 min read
·
Heather McKenzie
Press Releases
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
January 12, 2026
·
6 min read
Press Releases
Zylox-Tonbridge Hosts Investor Open Day, Showcasing Innovation Pipeline and Global Growth Strategy
January 12, 2026
·
3 min read
Press Releases
FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation
January 12, 2026
·
3 min read
Press Releases
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
January 12, 2026
·
5 min read
Press Releases
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
January 12, 2026
·
11 min read
Press Releases
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings - January 11, 2026
January 12, 2026
·
14 min read
Press Releases
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 12, 2026
·
5 min read
Press Releases
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
January 12, 2026
·
9 min read
1 of 86,871
Next
